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Abstract: 
Aim of study: Myelomeningocele (MMC) is the most common form of 
congenital neural tube defect. Current fetal surgical repair performed to 
prevent the exposed spinal cord from being injured until delivery cannot 
reverse those injuries already inflicted in utero. “Cell sheet” technology has 
been adopted successfully for the regeneration of diverse organs and tissues, 
although this promising modality has not yet been used for fetal therapy. This 
study thus tested our hypothesis that fetal MMC tissue histologically injured 
in utero could be regenerated using cell sheet technology.   
Methods: We used the L6 myoblast cell line derived from rat skeletal muscle 
for the cell sheet engineering. A fetal MMC model was also obtained from 
pregnant Sprague-Dawley (SD) rats fed orally with retinoic acid (60 mg/kg, 
embryonic day 10). Cell sheets were then transplanted onto the fetal MMC 
lesion (embryonic day 19) following maternal anesthesia, laparotomy, and 
hysterotomy. The incisional wound of the uterus was kept open for 4 hours 
under anesthesia with the MMC lesion maintained outside the body with the 
transplanted cell sheet. Subsequently, the experimental fetuses were 
sacrificed for histological (HE stain) and immunohistochemical studies to 
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evaluate viability and differentiation potential based on cell markers of the 
transplanted L6 myoblasts.  
Results and Discussion: Immunohistochemical studies clearly demonstrated 
cell-sheet markers specific to neurons, skeletal muscle, and myoblasts within 
the treated MMC lesions, confirming that the cell sheet was biologically 
implanted within 4 hours after the procedure.  
Conclusion: Cell sheet technology could be useful for intrauterine 
regeneration of the fetal rat spinal cord injured by an associated MMC. 
 
 
Key words: cell sheet, fetal myelomeningocele, transplantation, 
tissue regeneration  
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Introduction 
Myelomeningocele (MMC) is a congenital anomaly associated with 
potentially lifelong neurological disabilities that are closely related to the so-
called “two-hit” hypothesis (1). The first hit involves early-stage 
embryological abnormalities that result in the MMC morphology and the 
second hit involves environmentally acquired damage to the exposed spinal 
cord that lasts in utero until delivery. Although prenatal surgical repair of the 
MMC could prevent the second hit, this procedure is limited to 
morphological correction of the spinal cord and does not heal those injuries 
acquired before surgery (1).  
Regenerative medicine is increasingly expected to yield promising results in 
the field of prenatal medicine. Among diverse regenerative technologies, we 
used animal models of fetal MMC to focus on surgically transplanting a “cell 
sheet” onto the MMC lesion with potential full recovery of the fetal spinal 
cord architecture before birth. We previously found that such cell sheets 
could be biologically implanted and incorporated quite early after surgical 
application onto the fetal MMC (2). In this article, we present the outcomes 
of our experimental study and the future prospects of cell sheet technology 
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in the field of prenatal medicine. 
 
 
Materials and Methods 
 
Experimental animals: All animals were treated in accordance with the 
guiding principles for care and use of animals (National Center for Child 
Health and Development, Tokyo, Japan). Time-dated pregnant Sprague-
Dawley rats (E-10 days; Sankyo Labo Service Corporation, Inc., Tokyo, 
Japan) were gavage fed with retinoic acid dissolved in olive oil (60 mg/kg; 
Wako Pure Chemicals, Osaka, Japan). Both the retinoic acid-fed and non-
fed fetuses were harvested on E-19 or 21 days. The retinoic acid-fed fetuses 
were further divided into MMC-positive and -negative animals. In our study, 
the MMC-positive fetuses were likely to have no tail, thus we statistically 
assessed the coincidence of two findings: “having MMC” and “no tail 
development”. 
 
Cell culture and preparation of the cell sheet: L6 cells (rat myoblast cell line 
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derived from the skeletal muscle; American Type Culture Collection, 
Rockville, MD, USA) were grown to near confluence in DMEM (Gibco, 
Brooklyn, NY, USA) supplemented with 10% fetal bovine serum (Hyclone, 
Shrewsbury, NJ, USA), 100 IU/ml penicillin and 100 μg/ml streptomycin 
(Gibco, Brooklyn, NY, USA) on 25-cm2 tissue culture flasks (BD 
Biosciences, Franklin Lakes, NJ, USA). The L6 cells were then transferred 
to a “thermo-responsive culture dish”, which is coated with a temperature-
responsive polymer such that a simple temperature change from 37°C to 
32°C readily alters the dish surface from hydrophobic to hydrophilic. This in 
turn allows a sheet of cultured L6 myoblast cell clusters (cell sheet) to detach 
with cell connections and cell-to-cell communications well preserved. 
 
Cell sheet transplantation (CST): On E-19 days, pregnant rats were 
anesthesized with somnopentyl (Kyoritsu Seiyaku Corporation, Japan) and 
subjected to laparotomy. A small hysterotomy was made following a 6–0-
silk purse-string suture placed on the uterine wall. Then, after an amniotomy, 
the MMC lesion was exposed through the uterine wall. The cell sheet was 
then directly placed to cover the entire fetal MMC lesion, and after filling 
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the uterine cavity with warm saline, the hysterotomy site was closed for 4 h, 
during which the animals were maintained under anesthesia. Thereafter, the 
fetuses were harvested and fixed in neutral buffered 10% formalin (Sigma-
Aldrich, USA) for gross and microscopic studies including 
immunohistochemistry. 
 
Histological and immunohistochemical studies: After sequential processing, 
the fetuses were embedded in paraffin wax with the transplanted cell sheet 
and sectioned for histological analysis (5-μm-thick sections). The sections 
were then dewaxed, rehydrated, and HE stained. To evaluate viability and 
differentiating potential of the transplanted L6 cells, the sections were further 
analyzed immunohistochemically based on L6 myoblast markers specific to 
neurons, skeletal muscles, and myoblast cells (3). To do this, the sections 
were incubated with primary rabbit antibodies against polyclonal beta 3 
tubulin or polyclonal anti-nerve growth factor (NGF), and mouse 
monoclonal anti-smooth muscle actin (SMA) (Abcam, Cambridge, UK; 
dilution 1:100). Immunostained sections were examined using a 
conventional fluorescence microscope (Zeiss, Jena, Germany). 
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Results 
Experimental animals: There was no statistically significant correlation in 
the incidence of MMC between the fetuses observed at E-19 and E-21 days. 
Figure 2B shows that fetuses with no tail had a significantly high incidence 
of MMC. Accordingly, to accurately diagnose a fetus as having MMC 
without hysterotomy, it was practical and quite helpful to identify the fetal 
tail during these procedures by palpating the uterus from the outside. 
 
Histological and immunohistochemical studies of L6 cells and cell sheets 
transplanted onto fetal MMCs: Cultured L6 myoblast cells microscopically 
showed fibroblast-like and spindle-shaped morphology, which was 
unaffected by the length of culture. The HE staining shown in Fig. 3A 
indicates the viability of L6 cells in the transplanted cell sheet. The 
immunostaining shown in Figs. 3B, C, and D reveals that the cultured L6 
cells expressed SMA, NGF, and beta tubulin 3 markers, respectively. Figure 
4A shows HE staining of the transplanted cell sheet attached to the fetal 
MMC lesion, and the accompanying immunostaining in Figs. 4B, C, and D 
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shows positive reactions for SMA, NGF, and beta tubulin 3 in the attached 
cell sheet in the area where the cell sheet was transplanted. 
 
 
Discussion 
 
Our animal experimental model of MMC indicated that the sheet-like and 
viable L6 cell clusters (cell sheet) were likely to become attached 
biologically shortly after surgical transplantation onto the fetal MMC lesions, 
preventing its further histological aggravation in utero. This finding suggests 
that future human fetal MMC treatment using cell sheet technology could 
potentially promote prenatal regeneration of the exposed neural tissues 
injured in utero and thus further improve the lifelong neurological outcomes 
currently achieved with fetal surgical repair (4). Our conclusion is supported 
by the HE staining of tissue from the whole fetus in revealing that the 
adhering transplanted cell sheet remained viably attached to the fetal spinal 
cord at 4 hours after transplantation, with a well-preserved ECM. Positive 
immunostaining of the attached cell sheet for the intrinsic neuromuscular 
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growth factors NGF, SMA, and beta-tubulin 3 further strengthened the 
potential success of this technique by suggesting that the L6 cell sheet could 
enhance early regeneration of the neural tissue at the site of cell-sheet 
transplantation.  
 
Cell sheet technology as investigated here has already been reported 
experimentally and clinically to promote diverse tissue regeneration, and has 
been successfully employed in a variety of medical fields. For example, in a 
study using rabbit models, transplanted cell sheets enhanced epithelialization 
of laser-ablated tissues within 5 minutes, leading to complete re-
epithelization in 3 to 5 days, while in therapeutic ophthalmology, this 
technology enabled reduction in corneal haze after excimer laser 
keratectomy (5). In addition, a cell sheet derived from a patient’s oral 
mucosal epithelium was transplanted onto their eyes with improved clinical 
outcomes (6). In adult dogs with experimentally induced dilated 
cardiomyopathy (DCM), transplanting of a myoblastic sheet onto the left 
ventricle attenuated myocardial remodeling in 4 weeks with resultant 
improvement in cardiac function (7). Indeed, there are several clinically 
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successful cases of cell sheet technology reported for DCM (8, 9). 
Interestingly, mesenchymal stem cells (MSCs) prenatally injected into the 
MMC cord with growth factor(s) could also stimulate tissue regeneration 
(10). However, while this MSCs injection technique is seemingly less 
invasive, the cell sheet used herein contains its own built-in ECM without 
the need for extrinsic growth factor(s), making it superior in preventing the 
constituent L6 cells from being scattered. Furthermore, the sheet-like 
structure sealing the exposed MMC lesion should hopefully minimize 
aggravation of the in utero mechanical and chemotoxic injuries to the neural 
tissues (“second hit”).  
Our experimental study had three major limitations. First, without 
hysterotomy, we could not accurately diagnose a fetus as having MMC. In 
this regard, maternal laparotomy for locating the fetal tail was actually 
helpful in observing MMC through the stretched thin uterine wall. Second, 
it was difficult to keep the cell sheet attached to the MMC lesion securely 
within the amniotic fluid environment; however, in our experiment, the cell 
sheet transplanted onto the exposed spinal cord remained histologically 
attached in utero for at least 4 hours and seemed to promote tissue 
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regeneration much sooner than we had expected. In addition, it seems 
encouraging that the combined use of the gelatin-based scaffold and 
bioactive proteins reportedly promotes cellular ingrowth that could be 
accompanied by spinal cord regeneration (11), because the sheet-like cluster 
of L6 cells might also work as a kind of durable scaffold owing to the 
inherent ECM component. Lastly, we could not easily identify the best 
prenatal timing for cell sheet transplantation, but we believe that the clinical 
timing of fetal surgical repair of between 19 and 26 weeks of gestation could 
be used as a reference (12).  
 
Conclusion 
 
This feasibility study on the prenatal use of cell sheet technology suggests 
that sealing up the MMC lesion using an adherent cell sheet together with 
surgical repair could lead to more effective prenatal MMC repair. Further 
study of such techniques is needed to facilitate actual improvement in fetal 
treatment of MMC. 
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Figure legends: 
 
Fig. 1. A) MMC area of a fetus from outside the uterus. B) MMC inside the 
uterus after incision. C) Cell sheet transplantation on the MMC area. 254 x 
190 mm (96 x 96 DPI) 
 
Fig. 2. A) Number of fetuses on different embryonic days after retinoic acid 
induction. B) Number of defective fetuses after retinoic acid induction. 254 
x 190 mm (96 x 96 DPI) 
 
Fig. 3. A) H-E staining of the cell sheet. B, C, D) Immunostaining of smooth 
muscle actin, nerve growth factor, and beta tubulin 3, respectively, in L6 
myoblast cells (green – cell, blue – nucleolus). 254 x 190 mm (96 x 96 DPI) 
 
Fig. 4. A) H-E staining of the spinal cord at 4 hours after the cell sheet 
transplantation in an MMC-defective rat fetus. B, C D) Immunostaining of 
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NGF, SMA, and BETA3 of the transplanted cell sheet in the defective area, 
respectively. 254 x 190 mm (96 x 96 DPI) 




